News ImmuneRegen NewsNew Research Could Lead to Potential Treatment for Avian FluHead Researcher Available for Comment on Hong Kong Influenza Research, SARS, Avian Flu and how they are Connected Scottsdale, AZ - February 4, 2004 - With the re-emergence of SARS and another outbreak of Avian Flu in Asia, many government officials are concerned the outbreaks will increase and a new epidemic will emerge. In response to this threat, ImmuneRegen Biosciences, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (BULLETIN BOARD: IRBO), recently completed testing on the Hong Kong influenza virus, which is similar to that of SARS and the Avian Flu. Company executives believe this research may indicate efficacy of their proprietary compound, Homspera™, in treating the Hong Kong respiratory virus in mice. Additionally, Company executives believe these test results are vital to research designed to develop a treatment for SARS. The study, conducted at the University of Arizona Lung Injury Laboratory by Mark Witten, Ph.D., co-founder and acting head researcher of ImmuneRegen, was performed on 31 mice total. The results show that, of those mice treated with Homspera™, over 90% survived the lung injury. The mice not treated with Homspera™ had pathological signs of lung injury and showed actual Hong Kong influenza virons in the lung tissue. Homspera-treated mice had normal airways and no detectable Hong Kong influenza virons, which is an encouraging development given fears that the Avian flu reported in Vietnam had crossed with human flu genomes to produce a new strain of the virus - a strain to which humans may have no immune system recognition. Dr. Witten is currently available for comment on this potential treatment for the Hong Kong influenza virus, SARS, and Avian Flu. He is qualified to provide in-depth commentary on the following issues- • What is the Hong Kong virus and what causes it? About ImmuneRegen BioSciences, Inc.a wholly owned subsidiary of IR BioSciences Holdings, Inc., (OTC BB:IRBS.OB - News) is a development-stage biotechnology company focused on the research, development and licensing of Homspera™ and its derivatives. Homspera is an adult stem cell active compound that in study results has been shown to regenerate and strengthen the immune system and enhance wound healing. Viprovex®, a derivative of Homspera, is being developed for potential use against infectious diseases as a stand-alone or combination therapy and as a vaccine adjuvant. To advance its mission, the Scottsdale, Arizona based company has forged numerous study partnerships with industry and academic leaders, including Celgene Cellular Therapeutics, HemoGenix, Lovelace Respiratory Research Institute and Virion Systems. For more information, please visit www.immuneregen.com. Statements about ImmuneRegen's future expectations, including statements about the potential use and scientific results for ImmuneRegen's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. ImmuneRegen intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with ImmuneRegen's business, are subject to various risks and uncertainties. ImmuneRegen's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials), the evaluation of potential opportunities, the level of corporate expenditures and monies available for further studies, capital market conditions, and others set forth in ImmuneRegen's periodic report on Form 10-Q for the three months ended June 30, 2008 and on Form 10-KSB for the year ended December 31, 2007 as filed with the Securities and Exchange Commission. There are no guarantees that any of ImmuneRegen's proposed products will prove to be commercially successful. ImmuneRegen undertakes no duty to update forward-looking statements. Contact: or
### Copyright © 2003-2008, ImmuneRegen Biosciences, Inc. All rights reserved. |
|